查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179908

2023-2030 年全球胶质母细胞瘤治疗市场

Global Glioblastoma Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

胶质母细胞瘤也称为多形性胶质母细胞瘤 (GBM)。 胶质母细胞瘤是一种在大脑和脊髓中形成的侵袭性癌症。 胶质母细胞瘤由支持神经细胞的称为星形胶质细胞的细胞形成。 胶质母细胞瘤可以发生在任何年龄，但它往往更常发生在老年人身上。 治疗包括放疗、化疗和手术。

市场动态

政府和非政府组织正在努力提高人们对多形性胶质母细胞瘤的认识。 主要参与者的强大研发计划、多形性胶质母细胞瘤发病率上升以及美国 FDA 批准的新药增加是预测期内推动市场的因素。

世界各地的政府和非政府组织采取各种努力，通过教育多形性胶质母细胞瘤患者来提高认识，这有望推动市场增长。

移动消息平台 Ping Mobile 发起了一项移动活动，以提高人们对脑癌的认识。 这有助于提高人们对多形性胶质母细胞瘤的认识，并激励人们为多形性胶质母细胞瘤的研究工作捐款。 此外，美国脑肿瘤协会、加拿大脑肿瘤基金会和治愈脑癌基金会等组织也在做很多宣传工作，以提高公众对该病的认识。 在英国，三月是“脑肿瘤宣传月”，脑肿瘤研究的成员慈善机构发起了一项活动。 该活动的主要目的是提高人们对脑肿瘤研究资金短缺的认识，并提高人们对脑肿瘤及其治疗方法的认识。 Novocure 还在脑肿瘤宣传月期间开展了一场关于多形性胶质母细胞瘤的宣传活动。 这些因素正在推动预测期内的市场增长。

与治疗多形性胶质母细胞瘤相关的高成本是抑制市场增长的主要因素。

商业保险患者接受 TMZ 治疗的新诊断 GBM 的直接医疗费用很高，估计为 268,031 美元。 已经进行了广泛的研究以减少与胶质母细胞瘤患者护理相关的直接成本。 直接成本是归因于疾病的成本，例如与疾病的所有相关治疗和管理相关的成本，由各方（包括患者）承担，取决于保险状况等因素。存在这种可能性。 大部分直接费用发生在治疗的前四个月，费用稳定超过一年，反映出这种疾病的生存率很低。 放射和手术对 GBM 的直接成本贡献最大。 因此，预计上述因素将在预测期内阻碍市场。

COVID-19 影响分析

一般而言，癌症患者和胶质母细胞瘤患者发生严重急性呼吸系统综合症冠状病毒2型（SARS-CoV-2）并发症的风险高，感染风险和治疗的临床疗效都很高。一个平衡点是理想的。 该肿瘤组的侵袭性行为证明需要一个多学科团队来支持当前大流行期间的临床决策。 COVID-19 在实体瘤发生中的作用尚不清楚，也未见在神经胶质瘤病理生理学中的作用的报导。 已知神经胶质细胞和神经元在其表面表达 ACE2，神经元可能是 COVID-19 的感染目标。

当前的高级别胶质瘤 (HGG) 治疗指南提供了一个基于证据的护理框架，以改善无进展生存期和总生存期 (OS)。 在大流行期间，医生必须平衡弱势人群感染 COVID-19 的风险与癌症患者治疗不足的风险。 此外，社会需要保护医护人员并避免二次病毒传播给患者。 对于大多数神经肿瘤中心来说，在 COVID-19 大流行期间接触到胶质母细胞瘤患者是很困难的。 巴西各州之间的医疗差异使医生难以做出适当的治疗决定。 具有良好体能状态和分子特征的患者应接受标准治疗方案，包括切除和同步放化疗的最安全组合。

老年患者和体能状态不佳的患者应谨慎治疗，并应在 COVID-19 流行期间单独使用，除非体能状态良好的无并发症患者受益于替莫唑胺大分割方案。药物治疗方案似乎是最合适的. 当前形势对提供最佳医疗保健提出了新的挑战，找到与患者沟通的新方式至关重要。 然而，这种情况预计将在预测期内逐渐改善。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第4章市场动态

  • 市场影响因素
    • 司机
      • 通过世界各地政府和非政府组织开展的各种努力，通过教育多形性胶质母细胞瘤患者提高认识，预计将推动市场增长。
    • 约束因素
      • 与治疗多形性胶质母细胞瘤相关的高成本是限制市场增长的主要因素。
    • 市场机会
    • 影响分析

第五章行业分析

  • 搬运工的五种力量
  • 供应链
  • 定价分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按治疗类型分类

  • 化疗
    • 替莫唑胺
    • 贝伐单抗
    • 卡莫司汀
    • 其他
  • 免疫疗法
  • 电场疗法
  • 其他

第 8 章分子类型

  • 低分子化合物
  • 生物製品

第9章给药途径

  • 口语
  • 肠外

第 10 章最终用户

  • 医院
  • 诊所
  • 其他

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第13章公司简介

  • 基因泰克
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Amgen
  • Merck & Co., Inc
  • Teva Pharmaceutical Industries, Ltd.
  • Arbor Pharmaceuticals LLC
  • Sun Pharmaceutical Industries, Ltd.
  • F. Hoffman-La Roche
  • Novartis AG
  • Pfizer

第14章 全球胶质母细胞瘤治疗市场-DataM

简介目录
Product Code: DMPH3059

Market Overview

The global glioblastoma treatment market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Glioblastoma is also known as glioblastoma multiforme (GBM). Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. Glioblastoma forms from cells called astrocytes that support nerve cells. Glioblastoma can occur at any age but tends to occur more often in older adults. Treatments include radiation, chemotherapy and surgery.

Market Dynamics

Governments and non-government bodies undertake various initiatives to raise awareness about glioblastoma multiforme. Strong R&D Initiatives from key players, rising incidence of glioblastoma multiforme and increasing US FDA approval of new drugs are the factors to drive the market in the forecast period.

Increasing awareness by educating people living with glioblastoma multiforme through various initiatives undertaken by governments and non-government bodies across the globe is expected to drive market growth.

Ping Mobile, a mobile messaging platform, has launched a mobile campaign to increase awareness about brain cancer. This helps raise awareness about glioblastoma multiforme and motivates people to donate money for glioblastoma multiforme research activities. Moreover, organizations such as the National Brain Tumor Society, Brain Tumour Foundation of Canada, and Cure Brain Cancer Foundation are also involved in many awareness campaigns to raise awareness among people about the condition. In the U.K., March is Brain Tumor Awareness month, a campaign established by member charities of Brain Tumor Research. The campaign's main aim is to spread awareness about the lack of funding for brain tumor research, and it helps people understand brain tumors and their treatment. Additionally, Novocure undertook many activities to spread awareness about glioblastoma multiforme during Brain Tumor Awareness Month. These factors are driving the growth of the market in the forecast period.

The high cost associated with treating the glioblastoma multiforme is a major factor that hampers the market growth.

The direct medical costs of newly diagnosed TMZ-treated GBM in commercially insured patients are substantial, with estimated costs of $268,031. Extensive studies have been conducted to decrease the direct costs associated with care for patients with glioblastoma. Direct costs are those attributable to the disease, including all the associated therapies and costs associated with managing the disease, which may be borne by various parties (including the patient), depending on factors such as insurance status. The majority of direct costs were incurred in the first four months of treatment, with a plateau in costs beyond one year, reflecting the poor survival of this disease. Radiation and surgery contribute most to the direct costs of GBM. Thus, from the above factors, the market is expected to be hampered in the forecast period.

COVID-19 Impact Analysis

Cancer patients, in general, and glioblastoma patients, are at a higher risk of developing complications from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and striking a balance between the risk of infection and the clinical benefit of treatment is ideal. This group of tumors' aggressive behavior justifies the need for a multidisciplinary team to assist in clinical decisions during the current pandemic. COVID-19's role in the tumorigenesis of solid cancer is unknown, and its role in glioma pathophysiology has not been reported. Glial and neuronal cells are known to express ACE2 on their surfaces, making neuronal cells a potential target for COVID-19 infection.

The current high-grade glioma (HGG) treatment guidelines provide an evidence-based care framework to improve progression-free and overall survival (OS). During the pandemic, doctors must strike a balance between the risks of COVID-19 in a vulnerable population and the risk of under-treatment cancer patients. Furthermore, there is a societal need for healthcare workers to be protected and for secondary viral spread to patients to be avoided. Approaching glioblastoma patients during the COVID-19 pandemic is difficult in most neuro-oncology centers. Significant healthcare disparities between Brazilian states make it difficult for physicians to make appropriate treatment decisions. Patients with good performance status and molecular profile should receive the standard treatment protocol, including the safest resection and concurrent chemo-radiotherapy.

Older patients and those with poor performance status should be treated with caution, and a monotherapy regimen may be best suited during the COVID-19 pandemic unless patients with good performance status and no comorbidities benefit from hypofractionated protocols with temozolomide. The current situation adds new challenges to providing the best healthcare possible, and finding new ways to communicate with patients is critical. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Chemotherapy segment is expected to hold the largest market share in glioblastoma treatment market

Glioblastoma multiforme (GBM) is adults' most common primary brain tumor. No specific medications exist to treat GBM. However, certain conditions require medical treatment. For seizures, the patient usually is started on levetiracetam (Keppra), phenytoin (Dilantin), or carbamazepine (Tegretol). Levetiracetam is often used because it lacks the effects on the P450 system seen with phenytoin and carbamazepine, which can interfere with antineoplastic therapy. Chemotherapy is a common type of treatment for glioblastoma multiforme. Most patients begin chemotherapy two to four weeks after surgery, concurrently or shortly after radiation therapy. Chemotherapy is sometimes the primary treatment when a tumor cannot be surgically removed. It works by using powerful medications to destroy rapidly dividing cancer cells. These medications can be taken as pills, injected into a vein, or, in some cases, injected into the intrathecal space of the spine.

Chemotherapy for glioblastoma requires a high level of expertise because tumors are frequently made up of multiple types of cells. Some medications may kill some of these cells while allowing others to proliferate unhindered. As a result, medical oncologists must carefully tailor treatment plans for glioblastoma patients. These factors will drive the segment's growth during the forecast period. Efforts to develop new treatments have focused on discovering new drug targets and categorizing patients based on age and molecular cancer markers. Immunotherapy, RIT, or dietary treatments combined with standard radio(chemo)therapy are other promising research avenues currently in translational development. Patients undergoing chemotherapy are given drugs that are designed to kill tumor cells. The current gold standard of treatment for GBM is chemotherapy with temozolomide. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global glioblastoma treatment market

North America region accounted for the largest market share in 2021. Owing to significant market players, increasing healthcare awareness, and FDA approvals for novel drugs and the development of advanced treatment methods that counter glioma stem cells' resistive properties are also positively influencing market growth. Additionally, increasing research and development (R & R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated various biological drugs. These drugs assist in diminishing the side effects of the existing treatment methods, thus creating broader acceptance amongst patients. New drug approvals and launches for GBM treatment are expected to drive market growth in the region. For instance, in January 2020, Pfizer launched 'Zirabev' in the U.S. It is a bevacizumab biosimilar to Avastin, approved for treating recurrent glioblastoma multiforme.

Additionally, On April 09, 2021, Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm' with its lead drug candidate, lenzilumab, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM). Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the glioblastoma treatment market are Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries, Ltd., F. Hoffman-La Roche, Novartis AG and Pfizer.

On April 09, 2021, Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm' with its lead drug candidate, lenzilumab, today announced positive results from the Phase 1 safety and bioimaging trial of its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM).

Genentech Inc.:

Overview:

Genentech Inc. is a biotechnology company based in the United States that became a subsidiary of Roche in 2009. The company is dedicated to pioneering science to discover and develop medicines for people suffering from serious and life-threatening diseases. In the United States, Roche and Genentech merged their pharmaceutical operations. The Genentech campus in South San Francisco is now the headquarters for Roche's pharmaceutical operations in the United States. Genentech Research and Early Development is a separate entity within Roche. Roche Holding Ltd. owns 66 percent of Genentech but allows it to operate independently. Genentech discovers, develops, manufactures, and sells human pharmaceuticals to meet critical medical needs.

Product Portfolio:

Avastin (bevacizumab): Avastin (bevacizumab) is approved to treat glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).

The global glioblastoma treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. arket Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing awareness by educating people living with glioblastoma multiforme through various initiatives undertaken by governments and non-government bodies across the globe is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost associated with treating the glioblastoma multiforme is a major factor that hampers the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Chemotherapy*
      • 7.2.1.1. Temozolomide
      • 7.2.1.2. Introduction
      • 7.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 7.2.1.4. Bevacizumab
      • 7.2.1.5. Carmustine
      • 7.2.1.6. Others
  • 7.3. Immunotherapy
  • 7.4. Electric-field therapy
  • 7.5. Others

8. By Type of Molecule

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 8.1.2. Market Attractiveness Index, By Type of Molecule
  • 8.2. Small Molecules*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biologics

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
      • 9.2.1.1. Introduction
      • 9.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Parenteral

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user
  • 10.2. Hospitals*
      • 10.2.1.1. Introduction
      • 10.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecule
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Molecules
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Genentech*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Amgen
  • 13.3. Merck & Co., Inc
  • 13.4. Teva Pharmaceutical Industries, Ltd.
  • 13.5. Arbor Pharmaceuticals LLC
  • 13.6. Sun Pharmaceutical Industries, Ltd.
  • 13.7. F. Hoffman-La Roche
  • 13.8. Novartis AG
  • 13.9. Pfizer

LIST NOT EXHAUSTIVE

14. Global Glioblastoma Treatment Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us